



مركز الكويت لمكافحة السرطان
Kuwait Cancer Control Center

BEVAcizumab / IRINotecan 340 mg



Ministry of Health

Name: _____ **File #:** _____ **Ht (cm):** _____
Nationality: _____ **Civil ID:** _____ **Wt (Kg):** _____
Gender/Age: _____ **DOB:** _____ **BSA (m²):** _____

Indication(s): Ovarian Cancer / Uterine Cancer / Cervical cancer.

Central line: Available NA

Allergies: NKA Yes, specify; _____

Parameters: Initiate treatment only if ANC \geq 1000; HB \geq 80; Plt \geq 100,000; CrCl $>$ 45 ml/min.
 Urine dipstick \leq +2 (If Urine dipstick $>$ 2, Do urine protein/creatinine ratio And give bevacizumab if the ratio $<$ 2).
 BP \leq 150/90 mmHg.

Pre-treatment Medications: (30-60 min before starting treatment)

Ondansetron 8 mg PO/IV
 Dexamethasone 10 mg PO/IV
 Atropine 1 mg SC 30 min before Irinotecan

Standard Protocol:

DRUG	DOSE	ADMINISTRATION	DAYS
BEVAcizumab (Avastin®)	10 mg/kg	IV in 100 mL NS over 90 min. If the initial infusion is well tolerated, shorten second infusion to 60 min. If the second infusion is well tolerated, shorten the subsequent infusions to 30 min.	D1
IRINotecan	340 mg/m ²	IV in 500 mL D5W over 90 min.	D1
To be repeated every 2 weeks until disease progression or intolerable toxicity.			

Special instructions: IRINotecan 340 mg/m² is used for patients who don't take enzyme inducing drugs.

Treatment Description:

Cycle	Date	Avastin®	IRINotecan	Physician	Consultant
C# __					
C# __					
C# __					
C# __					
C# __					

Important Notes:

Reported grade 3/4 toxicities: None Hematological Non-Hematological

If yes; Did it indicate hospitalization? Yes No
 Did it indicate chemo-delay for \geq 7 days? Yes No
 Did it indicate dose reduction? Yes No
 Did it indicate G-CSF support? Yes No